Fig. 1 · Structure

Documents & Downloads

Reparixin

Cat. No. A12383 CAS 266359-83-5

CXCL8/CXCR1/2 Inhibitor

Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).

In Stock

Publications for Reparixin

2 publications citing this product

  1. Naour AL, .et al. , J Mol Cell Biol, 2019, Sep 3 PMID: 31504643
  2. Wigenstam E, .et al. , Toxicology, 2015, Feb 3;328:40-7 PMID: 25497111

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Reparixin (Repertaxin) showed noncompetitive CXCR1/2-inhibitory pharmacology in experiments using the (R)-compound salified with L-lysine. Migration responses were suppressed while CXCL8 radioligand binding was retained, supporting inhibition of receptor function without competitive displacement of CXCL8. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CXCR1wt 5.6 nM (IC50, in L1.2 cells)
CXCR1Ile43Val 80 nM (IC50, in L1.2 cells)
CXCR1 1 nM (IC50, in cells)
CXCR2 ∼100 nM (IC50, in cells)

Cellular Effect

Cell Line Activity Value Description Reference
L1.2 IC50 0.0056 μM Inhibition of CXCL8-induced cell migration in L1.2 cells expressing CXCR1 by chemotaxis assay [PMID: 17665889]
L1.2 IC50 0.08 μM Inhibition of CXCL8-induced cell migration in L1.2 cells expressing Ile43Val CXCR1 mutant by chemotaxis assay [PMID: 17665889]

Reparixin Research Summary

This section summarizes 2 in vitro studies and 3 in vivo studies of Reparixin from 3 published references. In vitro models include human PMN and CXCR1-transfected L1.2 cells.

Reparixin In Vitro Studies

For the reported Repertaxin lysine salt, chemotaxis IC50 values were 1 nM for CXCL8-stimulated human PMN and 400 nM for CXCL1-stimulated PMN. CXCR1- and CXCR2-transfected L1.2 cells gave 1 nM and approximately 100 nM, respectively. The differing CXCR2-associated values show the importance of cellular context. C5a- and fMLP-driven PMN migration and several other chemokine-receptor responses were spared. [1]

Chemotaxis selectivity of reported Repertaxin lysine salt

Cell-based study · Human polymorphonuclear cells (PMN), monocytes, and L1.2 cells expressing human chemokine receptors [1]

Reported inhibition was ligand/receptor and cellular-context dependent. CXCL8-directed migration was inhibited while several non-CXCL8-receptor responses were spared.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CXCL8-induced human PMN migrationIC50 1 nM[1]
CXCL1-induced human PMN migrationIC50 400 nM[1]
CXCL8-directed migration of CXCR1/L1.2 versus CXCR2/L1.2 cellsIC50 CXCR1: 1 nM; CXCR2: ≈100 nM[1]
Migration driven by control chemoattractants/receptorsQualitative selectivity No inhibition of PMN migration to C5a or fMLP, monocyte migration to CCL2, or tested CCR2b/CCR4/CCR5/CCR7 and CXCL12 responses.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series shown in Fig. 1; reported IC50 values below are assay endpoints, not treatment doses.
Exposure duration
Human PMN migration 45 min; monocyte migration 2 h.
Method
48-well microchemotaxis chamber for primary cells; Transwell migration for L1.2 cells. Agonists include 1 nM CXCL8 and 10 nM CXCL1 for primary PMN; Fig. 1e uses 10 nM CXCL8 for CXCR1/2 transfectants.
Vehicle
Saline (Reagents).
Reported limits
Pretreatment duration and L1.2 incubation duration not established in the selected main-text methods.
Methods and source locations

Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: (R)-Repertaxin L-lysine salt

Reported lysine-salt pharmacology only. No conversion of reported concentration/dose and no assumption of equivalent potency for an AdooQ lot.

Reagents and Migration methods; Results Selectivity of Repertaxin Inhibitory Activity; Fig. 1a,c-e,i and caption

CXCL8-induced human PMN migration: Primary-cell chemotaxis; Results calls Fig. 1a representative of six independent experiments. — Results Selectivity; Fig. 1a,c

CXCL1-induced human PMN migration: CXCL1 acts through CXCR2; cellular-context endpoint. — Results Selectivity; Fig. 1c

CXCL8-directed migration of CXCR1/L1.2 versus CXCR2/L1.2 cells: Transwell chemotaxis; Fig. 1e caption identifies receptors and agonists. — Results Selectivity paragraph following Fig. 1 caption; Fig. 1e

Migration driven by control chemoattractants/receptors: Fig. 1c-e; spontaneous migration was also reported unaffected (data not shown). — Results Selectivity; Fig. 1c-e

CXCL8 radioligand binding in the presence of Repertaxin

Biochemical assay · Human PMN and CXCR1-transfected L1.2 cells [1]

At 1 μM, the reported Repertaxin salt did not displace CXCL8 or shift the CXCR1 saturation curve, supporting noncompetitive receptor inhibition when interpreted with the migration assays.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CXCL8 binding, receptor number and affinity in PMN; saturation/displacement in CXCR1/L1.2 cellsQualitative ligand-binding result No competition of CXCL8 binding or dextral displacement of the saturation curve at 1 μM Repertaxin.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM Repertaxin; radiolabeled CXCL8 0.2 nM for the PMN displacement experiment; 15 pM–4 nM in CXCR1 saturation experiments; 20 pM in low-tracer displacement.
Method
Radioligand displacement and saturation binding. Nonspecific binding defined with 200-fold excess unlabeled CXCL8.
Vehicle
Saline (Reagents).
Reported limits
Binding incubation duration not established from the selected main text.
Methods and source locations

Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: (R)-Repertaxin L-lysine salt

Reported lysine-salt pharmacology only. No conversion of reported concentration/dose and no assumption of equivalent potency for an AdooQ lot.

Reagents and CXCL8 Binding methods; Results Selectivity paragraphs on radioligand binding; Fig. 1f-h and caption

CXCL8 binding, receptor number and affinity in PMN; saturation/displacement in CXCR1/L1.2 cells: PMN binding panel f: one experiment of six; transfectant panels g,h: one experiment of three. Vehicle and unlabeled-ligand controls. — CXCL8 Binding methods; Results radioligand paragraphs; Fig. 1f-h and caption

Reparixin In Vivo Studies

In male Wistar rats with mild intestinal ischemia/reperfusion injury, intravenous Repertaxin lysine salt reduced intestinal and lung vascular leakage and neutrophil accumulation in a dose-dependent manner over the reported 3–30 mg/kg range. Protection was strongest at 30 mg/kg. These were short-term pretreatment observations around reperfusion. [2]

In nude mice bearing ovarian tumors with mesenchymal stromal cells, the combination of AdooQ-supplied Reparixin and carboplatin was associated with lower tumor-associated luminescence than carboplatin alone. An added antitumor effect was absent after macrophage depletion, limiting the result to the tested stromal and immune context. The paper does not specify the Reparixin salt form or lot, and the reviewed methods do not establish matched solvent controls, limiting attribution to Reparixin alone. [3]

Reported Repertaxin lysine salt in mild intestinal reperfusion injury

Animal study · Male Wistar rats (200–220 g); mild intestinal ischemia/reperfusion, 30 min ischemia followed by 30 min reperfusion [2]

The reported salt reduced intestinal and lung vascular leakage and MPO-based neutrophil accumulation in a dose-dependent manner; the strongest reported protection was at 30 mg/kg.

Conditions shared by the study groups

Route
Intravenous
Frequency
One administration
Treatment course
5 min before reperfusion (Fig. 4 caption); endpoints after 30 min reperfusion
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Repertaxin dose series
3, 10 and 30 mg/kg (reported doses)
Vehicle-treated I/R rats; sham-operated baselineDose-dependent reductions in Evans blue leakage and MPO-based neutrophil recruitment in intestine and lung. Fig. 4 reports mean ± s.e.m. from at least 5–6 animals per group.[2]
Repertaxin dose series
Model: Male Wistar rats; mild intestinal I/R
Reported limits: Exact numerical means not reported as a table and not reconstructed from bars; Fig. 4 significance-symbol/caption mismatch prevents reliable panel-wise P-value attribution.
Methods and source locations

Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: (R)-Repertaxin L-lysine salt

Reported lysine-salt pharmacology only. No conversion of reported concentration/dose and no assumption of equivalent potency for an AdooQ lot.

Fig. 1 material caption; Animals and I/R treatment/control methods; permeability/MPO and statistics methods; mild I/R Results; Fig. 4a-d and caption

Repertaxin dose series · Fig. 1 material caption; Animals and I/R treatment/control methods; permeability/MPO and statistics methods; mild I/R Results; Fig. 4a-d and caption

Reparixin plus carboplatin in stromal-cell-associated ovarian tumor chemoresistance

Animal study · Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs [3]

MSCs diminished the tumor response to carboplatin. The Reparixin/carboplatin combination had lower tumor-associated luminescence than carboplatin alone in the MSC-containing setting. Without a specified matched solvent control, the contribution of Reparixin cannot be fully separated from formulation differences; monotherapy efficacy is not established.

Conditions shared by the study groups

Frequency
Reparixin three times/week; carboplatin every 7 days
Treatment course
Day 7 start, 3 weeks; in-vivo imaging Day 34 and terminal tissue/lavage luminescence Day 36
Vehicle
Reparixin DMSO/PBS (v/v; ratio unspecified); carboplatin saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SKOV-3 + MSC, carboplatin + Reparixin
Reparixin 30 mg/kg; carboplatin 200 μl/mouse of 4.5 mg/ml solution (as reported)
Untreated SKOV-3 and SKOV-3 + MSC groups; corresponding carboplatin-only groupsLower terminal summed organ and lavage luminescence than the MSC-containing carboplatin-only group (Fig. 4e,f); carboplatin response was weaker in the presence of MSCs.[3]
SKOV-3 + MSC, carboplatin + Reparixin
Model: Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs
Reported limits: Reparixin/carboplatin injection routes not specified; no Reparixin-only treatment group shown in Fig. 4; no exact luminescence values reconstructed; group-specific solvent control not documented.
Methods and source locations

Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: Reparixin (AdooQ Bioscience; form unspecified)

Mouse combination-treatment findings for the named supplier material; no specific A12383 lot, stereochemical assay or salt-form validation.

Results Implication of CXCR1/2 axis in OTC resistance to carboplatin; Fig. 4c-f and caption; Animals and In vivo experiments methods

SKOV-3 + MSC, carboplatin + Reparixin · Results Implication of CXCR1/2 axis in OTC resistance to carboplatin; Fig. 4c-f and caption; Animals and In vivo experiments methods

Macrophage depletion limits the Reparixin combination effect

Animal study · Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs; additional clodronate-liposome depletion intervention [3]

In macrophage-depleted tumor-bearing mice, adding Reparixin to carboplatin did not produce an additional antitumor effect. This limits the inference to an MSC/macrophage-dependent context.

Conditions shared by the study groups

Route
Reparixin/carboplatin: not specified; clodronate liposome: intraperitoneal
Frequency
Reparixin three times/week; carboplatin every 7 days; clodronate once/week
Treatment course
Clodronate began one day before cell administration, weekly for 4 weeks; cancer treatment Day 7 for 3 weeks; terminal Day 36
Vehicle
Reparixin DMSO/PBS (v/v, ratio unspecified); carboplatin saline; clodronate PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Macrophage-depleted combination comparison
Reparixin 30 mg/kg; carboplatin 200 μl/mouse of 4.5 mg/ml solution (as reported); clodronate liposomes 200 μl/mouse of 1.25 mg/ml solution
Clodronate-treated carboplatin group without Reparixin; nondepleted comparison groups in Fig. S7a,bNo additional reduction in terminal summed organ or lavage luminescence with added Reparixin after depletion (ns comparisons in Fig. S7a,b). Caption: 6 mice/group at the beginning of the experiments.[3]
Macrophage-depleted combination comparison
Model: Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs; clodronate liposome intervention
Reported limits: Final evaluable n not specified in Fig. S7 caption; ns does not demonstrate equivalence; depletion verification/empty-liposome controls are not established here.
Methods and source locations

Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: Reparixin (AdooQ Bioscience; form unspecified)

Mouse combination-treatment findings for the named supplier material; no specific A12383 lot, stereochemical assay or salt-form validation.

Results macrophage-depletion paragraph preceding peritoneal cytokine results; In vivo experiments methods; Supplementary PDF p. 9, Fig. S7a,b and caption

Macrophage-depleted combination comparison · Results macrophage-depletion paragraph preceding peritoneal cytokine results; In vivo experiments methods; Supplementary PDF p. 9, Fig. S7a,b and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 266359-83-5
Applications CXCL8/CXCR1/2 Inhibitor
Formula C14H21NO3S
Molecular Weight 283.39
Synonyms DF 1681Y; Repertaxin
SMILES
C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 52 mg/mL (183.49 mM)
Water Insoluble
Ethanol 52 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Reparixin Research References

  1. [1] Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury Proceedings of the National Academy of Sciences of the United States of America (2004). PMID: 15282370 DOI: 10.1073/pnas.0402090101 Source material
  2. [2] Souza DG, Bertini R, Vieira AT, et al. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury British journal of pharmacology (2004). PMID: 15302676 DOI: 10.1038/sj.bjp.0705862 Source material
  3. [3] Le Naour A, Prat M, Thibault B, et al. Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors Journal of molecular cell biology (2020). PMID: 31504643 DOI: 10.1093/jmcb/mjz090 Source material

Publications

2 publications citing this product

  1. Naour AL, .et al. , J Mol Cell Biol, 2019, Sep 3 PMID: 31504643
  2. Wigenstam E, .et al. , Toxicology, 2015, Feb 3;328:40-7 PMID: 25497111

Added to your cart

View Cart Checkout
Loading...